ROCKVILLE, Md., Feb. 26, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 13, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2024, and recent operational highlights.Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor webs ...

Goldman Sachs downgraded Regenxbio Inc RGNX, citing gene therapy’s appeal for wet AMD and diabetic retinopathy is uncertain, as most patients are elderly and newer anti-VEGF treatments offer longer-lasting effects at lower costs.Analyst Paul Choi writes that AbbVie Inc partnered ABBV-RGX-314 faces growing competition, with its invasive delivery method making it less favorable than rival treatments.Data from the ATMOSPHERE and ASCENT pivotal trials evaluating the safety and efficacy of the subretinal deliver ...

Shares of Regenxbio (RGNX) have gained 9.3% over the past four weeks to close the last trading session at $8.21, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.55 indicates a potential upside of 333%.The average comprises 11 short-term price targets ranging from a low of $22 to a high of $52, with a standard deviation of $10.42. While the lowest estimate indicates an increa ...

ROCKVILLE, Md., Jan. 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at the 21st Annual WORLDSymposium™ 2025, taking place in San Diego, CA February 3-7, 2025. The following presentations include an encore of the topline results from the pivotal phase of the Phase I/II/III CAMPSIITE® trial of RGX-121. Abstract Title: Audiol ...

Regenxbio (RGNX) closed the last trading session at $7.95, gaining 1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $36.36 indicates a 357.4% upside potential.The average comprises 11 short-term price targets ranging from a low of $22 to a high of $52, with a standard deviation of $9.66. While the lowest estimate indicates an increase of 176.7% from the current price level, the m ...

REGENXBIO to receive $110 million upfront, potential milestone payments of up to $700 million and meaningful double-digit royalties on net sales, and lead manufacturing Nippon Shinyaku to lead commercialization of first potential gene therapies for Mucopolysaccharidosis II (MPS II) and Mucopolysaccharidosis I (MPS I) in U.S. and Asia REGENXBIO retains rights to RGX-121 Priority Review Voucher (PRV) with potential accelerated approval expected in 2025; rolling BLA submission underway ROCKVILLE, Md., Jan. 1 ...

Alignment achieved with FDA on AFFINITY DUCHENNE® pivotal program and access to accelerated approval; BLA expected in 2026 Pivotal trial of RGX-202 is enrolling ambulatory patients aged 1 and above with first patient dosed Phase I/II data show RGX-202 recipients exceeding external natural history and established benchmarks for clinical outcomes Functional improvements seen in all patients treated with dose level 1 and dose level 2 at 12 and 9 months respectively New biomarker data confirms consistent robu ...

-       Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial and Michael Kelly, PhD, Chief Scientific Officer of CureDuchenneROCKVILLE, Md., Nov. 14, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a webcast to discuss the AFFINITY DUCHENNE® pivotal program and new clinical data, including the first functional data from the ongoing Phase I/II study of RGX-202, the company's next-generation gene therapy for the treatmen ...

Call Start: 16:30 January 1, 0000 5:24 PM ET REGENXBIO Inc. (NASDAQ:RGNX) Q3 2024 Earnings Call November 6, 2024 16:30 ET Company Participants Patrick Christmas - Chief Legal Officer Curran Simpson - President and Chief Executive Officer Mitchell Chan - Chief Financial Officer Steve Pakola - Chief Medical Officer Conference Call Participants Gospel Enyindah-Asonye - Morgan Stanley Mani Foroohar - Leerink Partners Jack Padovano - Stifel Luca Issi - RBC Capital Markets Paul Choi - Goldman Sachs Daniil Gatauli ...

Regenxbio (RGNX) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -0.86%. A quarter ago, it was expected that this biotechnology company would post a loss of $1.29 per share when it actually produced a loss of $1.05, delivering a surprise of 18.60%.Over the last four quarters, the company has ...